Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity

Cancer Gene Therapy

Volumn 18, Issue 11, 2011, Pages 785-794

  Fu, X ^a   Tao, L ^a   Rivera, A ^a   Xu, H ^a   Zhang, X ^a  

^a University of Houston   (United States)

Author keywords

cancer virotherapy; herpes simplex virus; innate immunity; neutrophil infiltration; oncolytic virus

Indexed keywords

HERPES SIMPLEX VIRUS FUSON H2; INTERFERON; ONCOLYTIC HERPES VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESOPHAGUS CANCER; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; ICP10 GENE; INNATE IMMUNITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL LINE; VIRUS GENOME; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; FEMALE; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNITY, INNATE; INTERFERONS; MICE; MICE, NUDE; NEOPLASMS; NEUTROPHILS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

MURINAE; SIMPLEXVIRUS;

EID: 80054748674     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.46     Document Type: Article

References (41)

1. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129. (Pubitemid 44547756)
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. (Pubitemid 38637993)
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. (Pubitemid 38720929)
4. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-976. (Pubitemid 41766784)
5. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells (see comments). Science 1996; 274: 373-376. (Pubitemid 26353341)
6. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856. (Pubitemid 121000529)
7. Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther 2001; 12: 921-932. (Pubitemid 32681856)
8. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. Systemic cancer therapy with a tumorselective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751-8757. (Pubitemid 34013887)
9. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656-4662.
10. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825. (Pubitemid 30469434)
11. van der Poel HG, Molenaar B, van Beusechem VW, Haisma HJ, Rodriguez R, Curiel DT et al. Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer. J Urol 2002; 168: 266-272. (Pubitemid 34640842)
12. Glasgow JN, Bauerschmitz GJ, Curiel DT, Hemminki A. Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther 2004; 4: 1-14. (Pubitemid 38854942)
13. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2003; 2: S157-S160.
14. Bell JC. Oncolytic viruses: what's next? Curr Cancer Drug Targets 2007; 7: 127-131. (Pubitemid 46348626)
15. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-6747. (Pubitemid 44876843)
16. Fu X, Tao L, Cai R, Prigge J, Zhang X. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 2006; 13: 882-890.
17. Fu X, Tao L, Li M, Fisher WE, Zhang X. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin Cancer Res 2006; 12: 3152-3157. (Pubitemid 43837364)
18. Fu X, Tao L, Zhang X. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther 2007; 14: 480-487. (Pubitemid 46588192)
19. Li W, Ding F, Zhang L, Liu Z, Wu Y, Luo A et al. Overexpression of stefin A in human esophageal squamous cell carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and metastasis. Clin Cancer Res 2005; 11: 8753-8762. (Pubitemid 43005926)
20. Wang B, Shi Q, Abbruzzese J, Xiong Q, Le X, Xie K. A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. Int J Gastrointest Cancer 2001; 29: 37-46.
21. Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RCJ et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane-fusion mechanisms. Clin Cancer Res 2003; 9: 2727-2733. (Pubitemid 36842119)
22. Boxio R, Bossenmeyer-Pourie C, Steinckwich N, Dournon C, Nusse O. Mouse bone marrow contains large numbers of functionally competent neutrophils. J Leukoc Biol 2004; 75: 604-611. (Pubitemid 38405651)
23. Borley AC, Hiscox S, Gee J, Smith C, Shaw V, Barrett-Lee P et al. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Res 2008; 10: R103.
24. Fu X, Nakamori M, Tao L, Amato R, Zhang X. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int J Oncol 2007; 30: 1561-1567.
25. Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006; 177: 8123-8132. (Pubitemid 44846331)
26. Chen YL, Chen SH, Wang JY, Yang BC. Fas ligand on tumor cells mediates inactivation of neutrophils. J Immunol 2003; 171: 1183-1191.
27. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: 'N1' versus 'N2' TAN. Cancer Cell 2009; 16: 183-194.
28. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007; 15: 1686-1693. (Pubitemid 47289013)
29. Grote D, Cattaneo R, Fielding AK. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res 2003; 63: 6463-6468. (Pubitemid 37255198)
30. van Heijst JW, Gerlach C, Swart E, Sie D, Nunes-Alves C, Kerkhoven RM et al. Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. Science 2009; 325: 1265-1269.
31. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999; 1: 241-263. (Pubitemid 129740012)
32. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997; 272: 28779-28785. (Pubitemid 27517837)
33. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008; 455: 674-678.
34. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009; 461: 788-792.
35. Zhong B, Yang Y, Li S, Wang YY, Li Y, Diao F et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 2008; 29: 538-550.
36. Lin R, Genin P, Mamane Y, Hiscott J. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol Cell Biol 2000; 20: 6342-6353. (Pubitemid 30650221)
37. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J 1998; 17: 1087-1095. (Pubitemid 28077662)
38. Wozniak A, Betts WH, Murphy GA, Rokicinski M. Interleukin-8 primes human neutrophils for enhanced superoxide anion production. Immunology 1993; 79: 608-615. (Pubitemid 23246899)
39. Oakes JE, Monteiro CA, Cubitt CL, Lausch RN. Induction of interleukin-8 gene expression is associated with herpes simplex virus infection of human corneal keratocytes but not human corneal epithelial cells. J Virol 1993; 67: 4777-4784. (Pubitemid 23215958)
40. Pan ZZ, Parkyn L, Ray A, Ray P. Inducible lung-specific expression of RANTES: preferential recruitment of neutrophils. Am J Physiol Lung Cell Mol Physiol 2000; 279: L658-L666.
41. Bellner L, Thoren F, Nygren E, Liljeqvist JA, Karlsson A, Eriksson K. A proinflammatory peptide from herpes simplex virus type 2 glycoprotein G affects neutrophil, monocyte, and NK cell functions. J Immunol 2005; 174: 2235-2241. (Pubitemid 40223970)